11 | DNA (Deoxyribonucleic Acid)IBA
01/2021
-
08/2004 |
11 | Podophyllotoxin (Condylox)FDA LinkGeneric
01/2019
-
11/2003 |
10 | Pharmaceutical PreparationsIBA
03/2022
-
03/2014 |
10 | Biological ProductsIBA
01/2019
-
10/2010 |
9 | Proteins (Proteins, Gene)FDA Link
01/2019
-
04/2011 |
7 | Chalcone (Benzalacetophenone)IBA
12/2020
-
08/2010 |
7 | ThiazolesIBA
10/2020
-
12/2014 |
7 | TubulinIBA
08/2019
-
05/2011 |
6 | Antineoplastic Agents (Antineoplastics)IBA
01/2021
-
01/2010 |
5 | pyrazoleIBA
02/2019
-
10/2014 |
5 | Etoposide (VP 16)FDA LinkGeneric
01/2018
-
08/2004 |
5 | BenzodiazepinesIBA
01/2018
-
08/2002 |
5 | benzimidazoleIBA
01/2018
-
08/2013 |
5 | Type II DNA Topoisomerases (Topoisomerase II)IBA
11/2015
-
08/2004 |
4 | Carbolines (Beta-Carbolines)IBA
12/2021
-
04/2014 |
4 | ProdrugsIBA
09/2019
-
05/2008 |
4 | 2-oxindole (oxindole)IBA
01/2018
-
12/2013 |
4 | FITC-annexin A5IBA
01/2018
-
10/2015 |
3 | Biomarkers (Surrogate Marker)IBA
02/2022
-
01/2015 |
3 | combretastatinIBA
01/2022
-
04/2016 |
3 | Tubulin ModulatorsIBA
12/2020
-
10/2018 |
3 | phenstatinIBA
12/2020
-
04/2015 |
3 | EnzymesIBA
07/2020
-
07/2008 |
3 | TankyrasesIBA
07/2020
-
01/2014 |
3 | benzothiazoleIBA
11/2019
-
01/2017 |
3 | OxindolesIBA
01/2019
-
07/2014 |
3 | LigandsIBA
01/2019
-
01/2012 |
3 | imidazopyridineIBA
10/2018
-
12/2013 |
3 | Dexamethasone (Maxidex)FDA LinkGeneric
01/2018
-
01/2014 |
3 | IminesIBA
01/2018
-
10/2004 |
3 | Reactive Oxygen Species (Oxygen Radicals)IBA
07/2016
-
01/2016 |
3 | pyrrolo(2,1-c)(1,4)benzodiazepineIBA
12/2013
-
10/2003 |
3 | pyrimidineIBA
10/2013
-
08/2012 |
2 | InterferonsIBA
02/2022
-
01/2018 |
2 | Antiviral Agents (Antivirals)IBA
02/2022
-
03/2021 |
2 | Leukocyte L1 Antigen Complex (Calgranulin)IBA
02/2022
-
11/2020 |
2 | OxadiazolesIBA
01/2021
-
10/2014 |
2 | Glucose (Dextrose)FDA LinkGeneric
12/2020
-
01/2017 |
2 | 5,5',6,6'- tetrachloro- 1,1',3,3'- tetraethylbenzimidazolocarbocyanineIBA
12/2019
-
01/2018 |
2 | Annexin A5IBA
12/2019
-
01/2018 |
2 | fosbretabulin (combretastatin A4)IBA
09/2019
-
10/2014 |
2 | CCAAT-Enhancer-Binding ProteinsIBA
01/2019
-
08/2018 |
2 | TriazolesIBA
10/2018
-
01/2017 |
2 | QuinazolinonesIBA
08/2018
-
01/2016 |
2 | Type I DNA Topoisomerases (Topoisomerase I)IBA
01/2018
-
11/2015 |
2 | ThiadiazolesIBA
01/2018
-
07/2014 |
2 | Cyclin D1IBA
04/2016
-
06/2010 |
2 | anthranilamideIBA
10/2013
-
08/2012 |
2 | benzamideIBA
09/2013
-
03/2012 |
2 | trioctyl phosphine oxide (TOPO)IBA
12/2010
-
08/2004 |
1 | SofosbuvirIBA
04/2022 |
1 | BilirubinIBA
04/2022 |
1 | Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 |
1 | SulfonesIBA
01/2022 |
1 | BromidesIBA
01/2022 |
1 | calcipotriene (calcipotriol)FDA LinkGeneric
09/2021 |
1 | betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric
09/2021 |
1 | Toll-Like Receptors (Toll-Like Receptor)IBA
09/2021 |
1 | Galectin 3 (LGALS3)IBA
03/2021 |
1 | Tumor Biomarkers (Tumor Markers)IBA
03/2021 |
1 | Aldehyde Reductase (Aldose Reductase)IBA
02/2021 |
1 | fidarestatIBA
02/2021 |
1 | phenanthreneIBA
01/2021 |
1 | sacubitril and valsartan sodium hydrate drug combinationIBA
01/2021 |
1 | Angiotensin Receptors (Angiotensin II Receptor)IBA
01/2021 |
1 | Neprilysin (Neutral Endopeptidase)IBA
01/2021 |
1 | 2,4-thiazolidinedione (thiazolidinedione)IBA
01/2021 |